期刊文献+

建立小鼠膀胱肿瘤原位模型的优化方法 被引量:1

Optimization for establishment of mouse models of orthotopic bladder tumors
下载PDF
导出
摘要 目的探讨硝酸银、盐酸、胰酶和乙醇预处理构建鼠膀胱肿瘤的成瘤机制。方法 24G静脉留置针插入膀胱,PBS冲洗后,将小鼠随机分为5组,每组6只:(1)乙醇作用组:22%乙醇0.1 mL保留20 min;(2)胰酶作用组:0.2%胰酶保留30 min;(3)酸碱作用组:0.1 mmol/L HCl 0.1 mL作用15 s后,PBS冲洗,0.1 mmol/L NaOH0.1 mL作用5 s,排空膀胱;(4)硝酸银作用组:0.15 mol/L硝酸银保留10 s;(5)对照组:0.1 mL生理盐水。术后1和24h随机处死每组3只小鼠,摘取膀胱,HE染色观察膀胱黏膜病理变化;戊二醛固定,电镜下观察膀胱黏膜细胞微结构变化;甲苯胺蓝染色,观察膀胱黏膜固有层肥大细胞数目变化;过碘酸-希夫(PAS)染色,观察膀胱黏膜GAG层变化。40只小鼠应用上述前四组预处理因素处理膀胱后,建立膀胱癌原位模型,计算各组成瘤率。结果胰酶和乙醇处理1h后,局部上皮伞状细胞脱落,黏膜下层暴露;酸碱和硝酸银处理组大部黏膜完整性破坏,黏膜下层暴露较多,连续性中断;对照组和实验组间炎症细胞浸润均不表现出统计学差异。24 h后,胰酶和乙醇组可见局部轻度水肿并充血,黏膜完整性恢复较好,细胞间见紧密连接;而酸碱和硝酸银组上皮黏膜薄厚不均一,仍可见部分脱落黏膜。结论利用硝酸银和酸碱预处理膀胱可作为鼠膀胱肿瘤原位模型构建的首选方法。 Objective To assess the efficacy of establishment of mouse models of orthotopic bladder tumor in- duced by pretreatment with silver nitrate, HCI, trypsin and ethanol. Methods Seventy 8- to 10-week old female C57BL/ 6 mice were anesthetized and catheterized with 24G i.v. catheter, then divided into 5 groups (n = 6 in each group) after washing the bladder with phosphate-buffered saline (PBS). ( 1 ) Ethanol group : incubation with 22% ethanol for 20 rain ; (2) Trypsin group: incubation with 0. 2% trypsin for 30 min; (3) HC1 group: pretreated with 0. 1 mmol/L HCI for 15 s and 0. 1 mmol/L NaOH for 5 s after washing the bladders with PBS; (4) Silver nitrate group: incubation with 0. 15 mol/ L silver nitrate for 10 s; (5) Vehicle group: normal saline. The mice were killed to obtain bladder tissue samples after 1 or 24 hours pretreatment. Pathological changes were observed using hematoxylin and eosin staining. The mieroenvironment modification was assessed by electron microscopy. Mast cells were counted with toluidine blue staining. The glycosamin- oglycan (GAG) layer was observed by periodic acid-Sehiff staining. Forty mice were intravesieally pretreated with the a- bove four reagents, respectively, then incubated with MB49 tumor cells for 2 hours, and the rate of tumor formation was de- termined. Results In the model mice, a part of umbrella cells were sloughed off, the submueosal layer was exposed and incontinuous in some areas at one hour after pretreatment with trypsin and ethanol. Mucosal damages were more serious in the HC1 and silver nitrate groups. However, there was no significant difference in the inflammatory cell infiltration between the experiment and control groups. Mild edema and congestion in the mucosa, tightly arranged epithelial cells, and contin- uous mucosa were observed in the mice after trypsin and ethanol pretreatment for 24 hours. By contrast, the thickness of mucosa was uneven and incomplete mueosa in some areas were still observed in the mice 24 hours after silver nitrate and HCL and NaOH pretreatment. The mice were sacrificed at 50 clays after tumor induction and the tumor formation rate was 100% in the mice pretreated with HC1, NaOH, and silver nitrate, respectively, 90% in the mice pretreated with tripsin, and 80% in the mice pretreated with ethanol (n = 10 in each group). Conclusions Pretreatment with silver nitrate and HC1, NaOH cause more serious damage in the bladder mueosa and may be regarded as an optimal choice in establishing or- thotopic bladder tumor models in mice.
出处 《中国实验动物学报》 CAS CSCD 2013年第4期30-34,I0005,I0006,共7页 Acta Laboratorium Animalis Scientia Sinica
基金 中央高校基本科研业务费专项资金项目(编号:lzujbky-2011-142)
关键词 膀胱肿瘤 原位模型 MB49细胞株 小鼠 Superficial bladder cancer Orthotopic tumor model Cell line, MB49 Mice
  • 相关文献

参考文献13

  • 1Lilly JD, Parsons CL. Bladder surface glycosaminoglycans is a human epithelial permeability barrier [ J]. Surg Gynecol Obstet. 1990, 171(6) : 493 -496.
  • 2Parsons CL, Boychuk D, Jones S, et al. Bladder surface glyco- saminoglycans: an epithelial permeability barrier [ J]. J Urel. 1990, 143(1) : 139 -142.
  • 3Parsons CL, Greene RA, Chung M, et al. Abnormal urinary po- tassium metabolism in patients with interstitial cystitis [ J ]. J Urol. 2005, 173 (4) :1182 - 1185.
  • 4Watanabe T, Shinohara N, Sazawa A, et al. An improved intra- vesical model using human bladder cancer cell lines to optimize gene and other therapies [ J ]. Cancer Gene Ther. 2000, 7 (12) : 1575 -1580.
  • 5Amit D, Hochberg A. Development of targeted therapy for blad- der cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences [ J ]. J Transiat Mede. 2010, 8 : 134.
  • 6. Chan E, Patel A, Heston W, et al. Mouse orthotopic models for bladder cancer research [J]. BJU Int. 2009, 104(9) : 1286 - 1291.
  • 7Soler B, Brosehini H, Martins JR, et al. Urinary glyeosamin- oglycans as biomarker for urothelial injury: is it possible to dis- criminate damage from recovery? [ J]. Urology. 2008, 72:937 - 942.
  • 8Watanabe FT, Chade DC, Reis ST, et al. Curcumin, but not Prima-1, decreased tumor cell proliferation in the syngeneic mu- fine orthotopic bladder tumor model [ J]. Clinics (Sao Panlo). 2011,66(12) : 2121 -2124.
  • 9Xiao Z, Hanel E, Mak A, et al. Antitumor efficacy of intravesi- cal BCG, gemcitabine, interferon-or and interleukin-2 as mono- or combination-therapy for bladder cancer in an orthotopic tumor model [ J]. Clin Med Insights Oncol. 2011, 5 : 315 - 323.
  • 10Jost SP, Gosling JA, Dixon JS. The morphology of normal human bladder urothelium [ J]. J Anat. 1989, 167 : 103 - 115.

二级参考文献10

  • 1杨慎敏,温端改,侯建全,何军,岑建农,陈剑华.原位膀胱癌动物模型的建立及应用[J].癌症,2007,26(4):341-345. 被引量:10
  • 2See WA, Chapman PH. Heparin prevention of tumor cell adherence and implantation on injured urothelial surfaces [J ]. J Urol, 1987, 138 (1): 182-6.
  • 3Chang SG, Kim JI, Jung JC, et al. Antimetastatic activity of the new platinum analog [Pt(cis-dach) (DPPE). 2NO3] in a metastatic model of human bladder cancer [J]. Anticancer Res, 1997, 17(5A): 3239-42.
  • 4Jiang F, Zhou XM. A model of orthotopic mufine bladder (MBT-2) tumor implants [J]. Urol Res, 1997, 25(3): 179-82.
  • 5Kleinerman DI, Dirmey CP, Zhang WW, et al. Suppression of human bladder cancer growth by increased expression of C-CAM1 gene in an orthotopic model [J]. Cancer Res, 1996, 56(15): 3431-5.
  • 6Watanabe T. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies [J]. Cancer Gene Ther, 2000, 7(12): 1575-80.
  • 7Asanuma H, Arai T, Seguchi K, et al. Successful diagnosis of orthotopic rat superficial bladder tumor model by ultrathin cystoscopy [ J]. J Urol, 2003, 169(2): 718-20.
  • 8Loskog A, Ninalga C, Hedlund T, et al. Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy [J]. Lab Anim, 2005, 39(4): 384-93.
  • 9Loskog A, Dzojic H, Vikman S, et al. Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor microenvironment [J]. J Immunol, 2004, 172(11): 7200-5.
  • 10Yang AS, Lattime EC. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses [J]. Cancer Res, 2003, 63(9): 2150-7.

共引文献8

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部